Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals... Show more
The 50-day moving average for KYKOY moved below the 200-day moving average on December 31, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The 10-day RSI Indicator for KYKOY moved out of overbought territory on January 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 15 cases where KYKOY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on January 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYKOY as a result. In of 15 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
KYKOY moved above its 50-day moving average on January 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KYKOY crossed bullishly above the 50-day moving average on January 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 58 cases where KYKOY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.448) is normal, around the industry mean (29.772). P/E Ratio (31.687) is within average values for comparable stocks, (74.035). KYKOY's Projected Growth (PEG Ratio) (4.832) is slightly higher than the industry average of (2.041). Dividend Yield (0.026) settles around the average of (0.029) among similar stocks. P/S Ratio (2.475) is also within normal values, averaging (112.501).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KYKOY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYKOY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric